Why the study?
Does the Ile164 beta2-adrenergic receptor polymorphism worsen the outcome of death or cardiac transplantation in patients with NYHA class II-IV heart failure?
Does the Ile164 beta2-adrenergic receptor polymorphism worsen the outcome of death or cardiac transplantation in patients with NYHA class II-IV heart failure?
The Ile164 beta2-adrenergic receptor polymorphism is associated with significantly worse survival and higher rates of cardiac transplantation in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Ile164 polymorphism linked to markedly worse HF outcomes; leaves open role in risk stratification or genotype-guided trials.
Liggett et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: